Kringle Pharma, Inc.
Tokyo Stock Exchange 4884.T
Kringle Pharma, Inc. EBT Margin for the year ending September 30, 2024: -943.25%
Kringle Pharma, Inc. EBT Margin is -943.25% for the year ending September 30, 2024, a 23.39% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.
-
Kringle Pharma, Inc. EBT Margin for the year ending September 30, 2023 was -1,231.28%, a -1,360.47% change year over year.
-
Kringle Pharma, Inc. EBT Margin for the year ending September 30, 2022 was -84.31%, a 18.48% change year over year.
-
Kringle Pharma, Inc. EBT Margin for the year ending September 30, 2021 was -103.42%, a -315.70% change year over year.
-
Kringle Pharma, Inc. EBT Margin for the year ending September 30, 2020 was -24.88%.
Key data
| Date | EBT Margin | Net Income Margin | EBITDA Margin | EBIT Margin |
|---|
Market news
Loading...
Tokyo Stock Exchange: 4884.T
| CEO | Kiichi Adachi Ph.D. |
| IPO Date | Dec. 28, 2020 |
| Location | Japan |
| Headquarters | 207 Saito Bio Incubator |
| Employees | 13 |
| Sector | Health Care |
| Industries | |
Description
Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Ibaraki, Japan.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email